SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Transgenic mouse model of hemophilia as a screen for immunogenicity of Factor VIII–based hemophilia therapies	A mouse model of hemophilia expressing human Factor VIII could help screen for risk of an immune reaction to Factor VIII–based hemophilia therapies. In the transgenic models, human Factor VIII did not elicit antibodies, whereas human von Willebrand factor (vWF) did result in vWF antibody production, suggesting tolerance toward Factor VIII. Also in the transgenic models, a pegylated form of human Factor VIII that was immunogenic in humans elicited antibodies, but a nonimmunogenic, pegylated form of Factor VIII did not. Future studies could include using the models to test other Factor VIII–based therapies for immunogenicity.	Patented by Baxter International Inc.; licensing status unavailable	Van Helden, P.M. *et al. Blood*; published online June 24, 2011; doi:10.1182/blood-2010-11-316521 **Contact:** Birgit M. Reipert, Baxter International Inc., Vienna, Austria e-mail: birgit_reipert@baxter.com

SciBX 4(27); doi:10.1038/scibx.2011.774
Published online July 14, 2011